Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 152 of 6351
-
Can magnetic pulses to the brain boost PTSD therapy?
Disease control Recruiting nowThe purpose of this study is to examine the benefits of combining repetitive Transcranial Magnetic Stimulation (rTMS) coupled with Cognitive Processing Therapy (CPT) in treating combat-related Posttraumatic Stress Disorder (PTSD) symptoms. The study will also examine change in de…
Sponsor: The University of Texas at Dallas • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can an enzyme replacement tame a rare metabolic disorder?
Disease control CompletedCAEB1102-300A is a multi-center randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pegzilarginase in patients with ARG1-D. This study will consist of a screening period; a randomized, double-blind treatment period; a long-term extension; and…
Phase 3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug combo aims to stop liver Cancer's return in High-Risk patients
Disease control OngoingA global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Supercharged immune cells take aim at childhood cancers
Disease control OngoingThis study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Because there is no standard treatm…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a pill stop desmoid tumors from growing?
Disease control CompletedThis study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into …
Phase 3 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma in major trial
Disease control CompletedThis is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approxi…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Chemo-Free hope: pill combo aims to shrink HER2+ breast tumors
Disease control CompletedThis is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade, versus t…
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug cocktail aims to improve multiple myeloma treatment before and after stem cell transplant
Disease control OngoingThis protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus the association of bortezomib, thalidomide and dexamethasone (VTd) as pre…
Phase 2 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
A tiny neck implant could catch Stroke-Causing clots before they reach the brain
Prevention OngoingThis study will assess the safety and performance of the Vine™ Embolic Protection System (embolic filtering device) in atrial fibrillation (AF) patients on top of oral anticoagulants (OAC), and remain at high risk for stroke recurrence. All patients will receive bilateral implant…
Sponsor: Javelin Medical • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
New drug duo shows promise against tough uterine cancer
Disease control CompletedThe purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Immunotherapy drug shows promise in preventing High-Risk skin cancer recurrence
Disease control CompletedThis is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cord blood treatment shows promise for tough leukemia cases
Disease control OngoingAllogeneic hematopoietic stem cell transplantation is a life-saving procedure in patients with blood cancers. Cord blood (CB) represents an alternative source of stem cells, which is associated with a lower risk of relapse, especially in the presence of minimal residual disease i…
Phase 2 • Sponsor: Ciusss de L'Est de l'Île de Montréal • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
A drop of blood could spot a deadly liver disease in newborns
Diagnosis CancelledOur study aims to develop a screening test for biliary atresia (BA) using dry blood spot to improve patient survival by early diagnosis. Newborn screening dry blood spot will be examined for the direct bilirubin (DB), γ-GT or matrix metalloproteinase-7 (MMP-7) levels. These findi…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
Can a Two-Drug immune combo shrink melanoma tumors?
Disease control CompletedThe main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.
Phase 2 • Sponsor: John Kirkwood • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Hope for NASH: new pill aims to reverse liver damage and prevent cirrhosis
Disease control OngoingA double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease
Phase 3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
HIV shot could replace daily pills for those who skip doses
Disease control OngoingThe purpose of this study was to compare the efficacy, safety, and durability of two different strategies to treat participants with a history of sub-optimal adherence and control of their HIV infection: long-acting (LA) antiretroviral therapy (ART) and all-oral standard of care …
Phase 3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cocktail of drugs shows promise for tough lung cancer
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer. The primary stud…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can a cancer drug slow ALS? a trial aims to find out
Disease control CompletedThis study consists of a phase 1 part and a phase 2 part. Phase 1 part: This is a phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of bosutinib to determine the maximum tolerated dose(MTD) and a recommended phase 2 dose (RP2D) of b…
Phase 1/2 • Sponsor: Kyoto University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can Metal-Stripping infusions save diabetic limbs and hearts?
Disease control OngoingTACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
Phase 3 • Sponsor: Mt. Sinai Medical Center, Miami • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Double-Drug attack shows promise against advanced melanoma
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advanced mel…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC